IL-6 inhibitors, including siltuximab, olokizumab, clazakizumab, PF-04236921, sirukumab, and elsilimomab, represent another class of therapeutics with demonstrated efficacy in conditions like Castleman disease and rheumatoid arthritis (51–55). This evidence concerns the gene IL6 and Castleman disease.